A Clinical Examination of Antibiotics in Continuous Regional Arterial Infusion (CRAI) Therapy for Severe Acute Pancreatitis (SAP)
-
- Yamasaki Shigemichi
- Emergency and Critical Care Center, Fukuoka University Hospital
-
- Ishikura Hiroyasu
- Emergency and Critical Care Center, Fukuoka University Hospital
-
- Kamitani Takanori
- Emergency and Critical Care Center, Fukuoka University Hospital
-
- Tanaka Junichi
- Emergency and Critical Care Center, Fukuoka University Hospital
-
- Nishizawa Shinya
- Emergency and Critical Care Center, Fukuoka University Hospital
-
- Koura Shinichi
- Department of Radiology, Fukuoka University Hospital
-
- Higashihara Hideyuki
- Department of Radiology, Fukuoka University Hospital
-
- Iwashita Hideyuki
- Department of Gastroenterology and Medicine, Fukuoka University Hospital
-
- Saka Akiko
- Department of Gastroenterology and Medicine, Fukuoka University Hospital
-
- Yoshikane Makoto
- Department of Gastroenterology and Medicine, Fukuoka University Hospital
-
- Sakisaka Shotaro
- Department of Gastroenterology and Medicine, Fukuoka University Hospital
Bibliographic Information
- Other Title
-
- 重症急性膵炎(SAP)に対する膵局所動注療法の使用抗菌薬に関する検討
- ─BIPMとIPM/CSの前向き無作為比較試験─
- -A Prospective Randomized Controlled Trial of BIPM and IPM/CS-
Search this article
Abstract
Continuous regional arterial infusion (CRAI) therapy using both protease inhibitors and antibiotics are one of the specific therapeutic methods for severe acute pancreatitis (SAP). As for the administered antibiotics, imipenem/cilastatin sodium (IPM/CS) is generally chosen as a first step, but there are only a few reports comparing IPM/CS with other antibiotics. Therefore, we performed a prospective randomized controlled trial between biapenem (BIPM) and IPM/CS as CRAI antibiotics. Twelve patients with SAP were admitted to our institution during April, 2009 since August, 2006, and were randomized into two groups. They were treated with 120mg/day of nafamostat mesilate and either 1.2g/day of BIPM (n=6) or 2.0g/day of IPM/CS (n=6) for CRAI therapy within 48 hours after the administration. The clinical data, inflammatory markers (WBC, CRP), serum pancreatic enzymes (lipase, tripsin, phospholipase A2, elastase 1 and pancreatic secretory trypsin inhibitor (PSTI) and contrast-enhanced abdominal Computed Tomography findings were compared between the two groups and the adverse effects were monitored. CRAI therapy was performed for seven days. The curative effect of this therapy was evaluated at the beginning of the treatment, the day 7 and the day 14. Our results suggested that BIPM was a non-recessive antibiotic which had an equal effect in CRAI therapy in comparison with IPM/CS.
Journal
-
- Nihon Fukubu Kyukyu Igakkai Zasshi (Journal of Abdominal Emergency Medicine)
-
Nihon Fukubu Kyukyu Igakkai Zasshi (Journal of Abdominal Emergency Medicine) 31 (5), 705-712, 2011
Japanese Society for Abdominal Emergency Medicine
- Tweet
Keywords
Details 詳細情報について
-
- CRID
- 1390001204733311488
-
- NII Article ID
- 10029879944
-
- NII Book ID
- AN10426469
-
- ISSN
- 18824781
- 13402242
-
- Text Lang
- ja
-
- Data Source
-
- JaLC
- CiNii Articles
-
- Abstract License Flag
- Disallowed